Please assess the completion status of the following clinical trial:

Trial Title: Secondary Prophylaxis Gastric Variceal Bleed

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with GOV2 without esophageal varix or IGV1, who had bled from GV were included~Exclusion Criteria:~* Presence of esophageal varix~* GOV2 with GOV1; contraindications to beta-blocker therapy and cyanoacrylate injection~* Prior injection of cyanoacrylate or sclerotherapy for GV or GV ligation, transjugular intrahepatic portosystemic shunt, balloon-occluded retrograde transvenous obliteration, balloon-occluded endoscopic injection sclerotherapy of GV, shunt operation for prevention of rebleeding from GV~* Patients already on beta-blocker or nitrates~* Undetermined origin of bleeding from esophageal varix or gastric varix~* Hepatic encephalopathy grade III/IV~* Hepatorenal syndrome~* Hepatocellular carcinoma~* Presence of deep jaundice (serum bilirubin \> 10 mg/dl)~* Uremia~* Cerebrovascular accident~* Cardiorespiratory failure~* Pregnancy or patients not giving informed consent for endoscopic procedures

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1. Endoscopic Cyanoacrylate injection (Type: ACTIVE_COMPARATOR): Endoscopic Cyanoacrylate injection in the gastric varix
- 2. Beta-blocker (Type: PLACEBO_COMPARATOR): Propranolol was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was \>90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure \<90 mm Hg or pulse rate \<55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.

Based on this trial design, predict the completion outcome and termination type (if applicable).